These product press releases are intended for use in the United States only. Countries outside of the U.S. may have different regulatory requirements and review practices that may require referencing different information. 22 Jun 2009  Merck & Co., Inc. and Drugs for Neglected Diseases initiative Collaborate to Find Treatments for World's Most Neglected Tropical Diseases 05 Jun 2009  Rolofylline Did Not Demonstrate Efficacy for Acute Heart Failure in Clinical Trial 01 Jun 2009  AstraZeneca and Merck & Co., Inc. Form Pioneering Collaboration to Investigate Novel Combination Anticancer Regimen 08 May 2009  Studies of GARDASIL®, Merck's Cervical Cancer Vaccine, and HPV 16 Vaccine Component of GARDASIL Presented at International Papillomavirus Conference 23 Apr 2009  Merck Announces Interim Phase IIa Study Results of MK-7009, an Investigational Oral Hepatitis C Virus Protease Inhibitor, in Patients with Chronic Hepatitis C 21 Apr 2009  Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile Infection 08 Apr 2009  Merck & Co., Inc. and Cardiome Sign License Agreement for Vernakalant, an Investigational Drug for Treatment of Atrial Fibrillation 09 Feb 2009  Data from ISENTRESS®, Merck's HIV Integrase Inhibitor, in Patients Whose HIV is Controlled on a Lopinavir/Ritonavir-Based Therapy Presented at the 16th Conference on Retroviruses and Opportunistic Infections 09 Feb 2009  Phase III Studies Showed ISENTRESS® in Combination Therapy Provided Significant Viral Load Reductions through 96 Weeks in Treatment-Experienced Patients with Triple-Class Resistant HIV

*Software to view files presented in PDF or SWF format is available at no charge through the Adobe Web site. Get Adobe Reader Get Adobe Flash Player

Printer Friendly Page